Market Overview

UPDATE: Wedbush Securities Raises PT to $105 on HeartWare International as FDA Approves HVAD

Share:
Related HTWR
Contemporary Results From Commercial HVAD System Registries Highlighted At ISHLT Meeting
18 Biotech Stocks These Wall Street Analysts Are Tracking

Wedbush Securities reiterated its Outperform rating on HeartWare International (NASDAQ: HTWR) and increased its price target from $101 to $105.

Wedbush Securities commented, "FDA approves HVAD for Bridge-to-Transplant (BTT). The good: sintered device and non-restrictive label. The not-as-good: Label includes DT data snapshot with stroke rate imbalance. Favorable overall and maintain expectations for HVAD to take majority share of US BTT market by 2014. … We spoke with a number of US LVAD physicians at the American Heart Association (AHA) conference earlier this month and heard a unanimous opinion that the HVAD does not have a devicespecific thrombosis issue. Moreover, those with limited or no experience using the HVAD in clinical studies appear eager to test-drive the device."

HeartWare International closed at $89.54 on Tuesday.

Latest Ratings for HTWR

DateFirmActionFromTo
May 2015BarclaysMaintainsOverweight
Apr 2015OppenheimerMaintainsOutperform
Feb 2015Canaccord GenuityMaintainsBuy

View More Analyst Ratings for HTWR
View the Latest Analyst Ratings

Posted-In: Wedbush SecuritiesAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (HTWR)

Around the Web, We're Loving...

Get Benzinga's Newsletters